MX2015016783A - Inhibidores de moleculas pequeñas de fibrosis. - Google Patents
Inhibidores de moleculas pequeñas de fibrosis.Info
- Publication number
- MX2015016783A MX2015016783A MX2015016783A MX2015016783A MX2015016783A MX 2015016783 A MX2015016783 A MX 2015016783A MX 2015016783 A MX2015016783 A MX 2015016783A MX 2015016783 A MX2015016783 A MX 2015016783A MX 2015016783 A MX2015016783 A MX 2015016783A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- small molecule
- molecule inhibitors
- inhibitors
- compositions
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Agronomy & Crop Science (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832768P | 2013-06-07 | 2013-06-07 | |
| PCT/US2014/041174 WO2014197738A1 (en) | 2013-06-07 | 2014-06-05 | Small molecule inhibitors of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015016783A true MX2015016783A (es) | 2016-07-18 |
Family
ID=52008597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016783A MX2015016783A (es) | 2013-06-07 | 2014-06-05 | Inhibidores de moleculas pequeñas de fibrosis. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9663499B2 (enExample) |
| EP (2) | EP3003038B1 (enExample) |
| JP (1) | JP6414831B2 (enExample) |
| KR (1) | KR102240329B1 (enExample) |
| CN (1) | CN105392364B (enExample) |
| AU (1) | AU2014274830B2 (enExample) |
| BR (1) | BR112015030203A2 (enExample) |
| CA (1) | CA2913634C (enExample) |
| CL (1) | CL2015003569A1 (enExample) |
| DK (1) | DK3003038T3 (enExample) |
| EA (1) | EA201592157A1 (enExample) |
| ES (2) | ES2755125T3 (enExample) |
| HK (1) | HK1221606A1 (enExample) |
| MX (1) | MX2015016783A (enExample) |
| PE (1) | PE20160523A1 (enExample) |
| PL (1) | PL3003038T3 (enExample) |
| PT (1) | PT3003038T (enExample) |
| SG (1) | SG11201510011VA (enExample) |
| TN (1) | TN2015000519A1 (enExample) |
| WO (1) | WO2014197738A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| KR102240329B1 (ko) | 2013-06-07 | 2021-04-14 | 더 스크립스 리서치 인스티튜트 | 섬유증의 소분자 억제제 |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| EP3250036B1 (en) * | 2014-12-10 | 2021-05-12 | The Scripps Research Institute | Small molecule inhibitors of fibrosis |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| WO2017184586A1 (en) * | 2016-04-18 | 2017-10-26 | The Trustees Of Columbia University In The City Of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash) |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN106866459A (zh) * | 2017-03-30 | 2017-06-20 | 成都绿林科技有限公司 | 一种抗真菌药物中间体的制备方法 |
| CN106986787A (zh) * | 2017-03-30 | 2017-07-28 | 成都绿林科技有限公司 | 一种泊沙康唑中间体的合成方法 |
| CN112040950A (zh) * | 2018-03-19 | 2020-12-04 | 上海偕怡医药科技有限公司 | 治疗特发性肺纤维化的方法和组合物 |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| EP3863723A4 (en) * | 2018-10-14 | 2022-09-07 | The University of Chicago | Compositions and methods for activating nrf2-dependent gene expression |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| US20210308089A1 (en) * | 2020-04-07 | 2021-10-07 | Amarin Pharmaceuticals Ireland Limited | Methods of treating and/or preventing viral infections and/or diseases caused by viruses in a subject in need thereof |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4619931A (en) | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| US4791111A (en) | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
| IL103558A0 (en) | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
| CA2176937A1 (en) | 1993-11-19 | 1995-05-26 | Carlton Edwin Ash | Polyketone polymer composition |
| US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| US5625064A (en) | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
| TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
| EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US6608101B1 (en) | 2000-06-20 | 2003-08-19 | Atherogenics, Inc. | 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders |
| EP1511490A4 (en) | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| CA2709203A1 (en) | 2007-12-13 | 2009-06-18 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| WO2010021681A2 (en) | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20110183948A1 (en) | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
| GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| WO2012047762A2 (en) | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
| CN103596566B (zh) | 2010-12-07 | 2017-08-25 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| WO2013036866A1 (en) * | 2011-09-07 | 2013-03-14 | The Johns Hopkins University | Itraconazole analogs and use thereof |
| US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
| AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| EP3004106B1 (en) | 2013-06-07 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Dual selective pi3 delta and gamma kinase inhibitors |
| KR102240329B1 (ko) | 2013-06-07 | 2021-04-14 | 더 스크립스 리서치 인스티튜트 | 섬유증의 소분자 억제제 |
-
2014
- 2014-06-05 KR KR1020157036822A patent/KR102240329B1/ko active Active
- 2014-06-05 EP EP14807059.2A patent/EP3003038B1/en active Active
- 2014-06-05 EP EP19191562.8A patent/EP3626242B1/en active Active
- 2014-06-05 CA CA2913634A patent/CA2913634C/en active Active
- 2014-06-05 TN TN2015000519A patent/TN2015000519A1/en unknown
- 2014-06-05 ES ES14807059T patent/ES2755125T3/es active Active
- 2014-06-05 US US14/895,813 patent/US9663499B2/en active Active
- 2014-06-05 EA EA201592157A patent/EA201592157A1/ru unknown
- 2014-06-05 WO PCT/US2014/041174 patent/WO2014197738A1/en not_active Ceased
- 2014-06-05 BR BR112015030203A patent/BR112015030203A2/pt not_active IP Right Cessation
- 2014-06-05 AU AU2014274830A patent/AU2014274830B2/en active Active
- 2014-06-05 DK DK14807059T patent/DK3003038T3/da active
- 2014-06-05 MX MX2015016783A patent/MX2015016783A/es unknown
- 2014-06-05 CN CN201480032411.7A patent/CN105392364B/zh active Active
- 2014-06-05 PT PT148070592T patent/PT3003038T/pt unknown
- 2014-06-05 ES ES19191562T patent/ES2991873T3/es active Active
- 2014-06-05 SG SG11201510011VA patent/SG11201510011VA/en unknown
- 2014-06-05 PE PE2015002576A patent/PE20160523A1/es not_active Application Discontinuation
- 2014-06-05 PL PL14807059T patent/PL3003038T3/pl unknown
- 2014-06-05 HK HK16109962.7A patent/HK1221606A1/zh unknown
- 2014-06-05 JP JP2016518012A patent/JP6414831B2/ja active Active
-
2015
- 2015-12-07 CL CL2015003569A patent/CL2015003569A1/es unknown
-
2017
- 2017-04-14 US US15/488,206 patent/US9981956B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014274830A1 (en) | 2015-11-26 |
| EP3626242A1 (en) | 2020-03-25 |
| JP6414831B2 (ja) | 2018-10-31 |
| SG11201510011VA (en) | 2016-01-28 |
| WO2014197738A1 (en) | 2014-12-11 |
| KR20160029028A (ko) | 2016-03-14 |
| PE20160523A1 (es) | 2016-05-25 |
| US9663499B2 (en) | 2017-05-30 |
| DK3003038T3 (da) | 2019-11-11 |
| US20170217943A1 (en) | 2017-08-03 |
| KR102240329B1 (ko) | 2021-04-14 |
| BR112015030203A2 (pt) | 2017-07-25 |
| EP3626242B1 (en) | 2024-08-07 |
| CN105392364B (zh) | 2018-09-14 |
| HK1221606A1 (zh) | 2017-06-09 |
| US20160130258A1 (en) | 2016-05-12 |
| EA201592157A1 (ru) | 2016-05-31 |
| TN2015000519A1 (en) | 2017-04-06 |
| EP3003038A4 (en) | 2016-11-16 |
| CN105392364A (zh) | 2016-03-09 |
| PL3003038T3 (pl) | 2020-02-28 |
| EP3003038B1 (en) | 2019-08-14 |
| CA2913634A1 (en) | 2014-12-11 |
| ES2755125T3 (es) | 2020-04-21 |
| PT3003038T (pt) | 2019-11-19 |
| ES2991873T3 (es) | 2024-12-05 |
| CL2015003569A1 (es) | 2016-11-11 |
| US9981956B2 (en) | 2018-05-29 |
| CA2913634C (en) | 2022-08-09 |
| EP3003038A1 (en) | 2016-04-13 |
| JP2016521710A (ja) | 2016-07-25 |
| AU2014274830B2 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000519A1 (en) | Small molecule inhibitors of fibrosis | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| EP3030323A4 (en) | Kdm1a inhibitors for the treatment of disease | |
| IL241322A0 (en) | Indoleamine 2, 3-dioxygenase (ido) inhibitors | |
| EP3256218A4 (en) | Kdm1a inhibitors for the treatment of disease | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| BR112016021012A2 (pt) | composições farmacêuticas de compostos terapeuticamente ativos. | |
| EP3221341A4 (en) | Therapeutic variant alpha-2-macroglobulin compositions | |
| MX2015008829A (es) | Momelotinib deuterado. | |
| IL242968A0 (en) | 17-nitrogen-modified astratrienethiazole derivatives that are medically active as inhibitors of 17.beta-hydroxysteroid dehydrogenase | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| ZA201700518B (en) | Use of active compound compositions | |
| PH12016501183A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| PH12016501182A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| PH12016501184A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| MX2016005160A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| MX2016005539A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| MX2016013428A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| GB201508787D0 (en) | Pharmaceutically active compounds | |
| GB201519919D0 (en) | Pharmaceutically active compounds | |
| GB201403538D0 (en) | Pharmacologically active compounds | |
| UA100326U (ru) | Применение натриевой соли гидрогенсульфида для потенцирования анальгетического эффекта нестероидных противовоспалительных препаратов |